What is Altis Biosystems?
Altis Biosystems operates at the intersection of biotechnology and preclinical research, specializing in the development of the proprietary RepliGut Systems. These innovative in vitro models are engineered to replicate the complex physiological environment of the human gut, providing pharmaceutical firms with a high-fidelity platform for drug development and disease modeling. By offering a sophisticated alternative to traditional testing methods, the company enables researchers to identify effective compounds with greater precision, thereby reducing reliance on animal testing and enhancing the efficiency of clinical trials. Their focus on conditions such as inflammatory bowel disease positions them as a key player in the precision medicine landscape, where rapid screening and actionable data insights are paramount for successful therapeutic outcomes.
How much funding has Altis Biosystems raised?
Altis Biosystems has raised a total of $3.2M across 2 funding rounds:
Angel/Seed
$3.1M
Debt
$131K
Angel/Seed (2020): $3.1M with participation from Hatteras Venture Partners, RTP Capital Group, VentureSouth, Atlanta Technology Angels, and Central Texas Angel Network
Debt (2021): $131K led by PPP
Key Investors in Altis Biosystems
Hatteras Venture Partners
A venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing both capital and strategic recruitment support.
Central Texas Angel Network
A prominent Austin-based angel investment firm that connects accredited investors with promising startups to foster regional economic growth and provide mentorship.
Atlanta Technology Angels
A leading angel investor network in Georgia that supports early-stage technology companies through financial investment, industry expertise, and mentorship.
What's next for Altis Biosystems?
With the infusion of this recent capital, Altis Biosystems is well-positioned to scale its operations and expand its market reach within the global pharmaceutical industry. The strategic roadmap likely involves enhancing the throughput of their screening services and deepening their research capabilities to address a broader spectrum of gastrointestinal pathologies. As the demand for more accurate, human-relevant preclinical data continues to rise, Altis Biosystems is expected to leverage its technological edge to forge deeper partnerships with major drug developers. This growth trajectory suggests a transition from early-stage innovation toward broader commercial adoption, potentially setting new standards for preclinical testing protocols and accelerating the time-to-market for life-saving therapies.
See full Altis Biosystems company page
